Clever Leaves Strengthens Its Presence in the U.S. Through Partnership With Biom Therapeutics
April 20 2022 - 08:45AM
GlobeNewswire Inc.
Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves”
or the “Company”), a leading multinational operator and licensed
producer of pharmaceutical-grade cannabinoids today announced a
two-year supply agreement with American, clinical-stage
biopharmaceutical company, Biom Therapeutics (“Biom”) to provide
high quality CBD isolate.
Clever Leaves has already provided Biom
Therapeutics with the first shipment of EU GMP compliant CBD
isolate to be manufactured by Biom into formulations for use in
studies and clinical trials for rare neurological and developmental
diseases.
“We are grateful for the opportunity to deliver
high-quality, pharmaceutical-grade, CBD products to help advance
medical cannabis research in the United States through our new
partnership with Biom Therapeutics,” said CEO of Clever Leaves,
Andres Fajardo. “The United States market is a key focus for Clever
Leaves in 2022 and partnering with strong biopharmaceutical
companies like Biom Therapeutics will help us further grow our
pharmaceutical presence and establish our superior standard of
product quality in the United States.”
Since its beginnings Clever Leaves has had the
mission to work to supply medicinal grade products to help patients
around the world. To date the company has multiple international
certifications, including European Union Good Manufacturing
Practices (EU GMP), that allow it to be a reliable supplier to its
customers, either in the field of research or providing its
portfolio of products to different types of customers in more than
15 countries around the world.
“We believe medical cannabis will be in
mainstream medicine for chronic illness in the coming years, and we
wanted to reinforce our partnership with industry leaders and
leading researchers in this emerging field,” said Dr. Bobban
Subhadra, CEO of Biom Therapeutics. “BIO017 is a novel drug
formulation for rare epilepsies that require high purity
cannabidiol. Clever Leaves has the state-of-the-art cGMP facilities
to make high-purity USP grade Cannabidiol; we are quite excited to
partner with Clever leaves to procure our drug substance for our
BIO017 formulation,” he added.
Biom has already shown the clinical benefits of
cannabidiol in epilepsy patients and obtained their Orphan Drug
Designation in 2021. “Showing safety & efficacy results for
this unmet need is a significant step in our long-term goals to
commercialize a superior drug. We plan to start our Phase-3
clinical studies in Angelman Syndrome patients in Q3 of 2023. We
are excited and look forward to our ongoing collaborations with
Clever Leaves,” said John Allen, President, Biom Therapeutics.
About Clever Leaves Holdings
Inc.Clever Leaves is a leading multinational operator and
licensed producer of pharmaceutical-grade cannabinoids. Its
operations in Colombia and Portugal produce cannabinoid active
pharmaceutical ingredients (API) and finished products in flower
and extract form to a growing base of B2B customers around the
globe. Clever Leaves aims to disrupt the traditional cannabis
production industry by leveraging environmentally sustainable,
ESG-friendly, industrial-scale and low-cost production methods,
with the world’s most stringent pharmaceutical quality
certifications.
For more information, please visit
https://cleverleaves.com/en/home/ and follow Clever Leaves on
Twitter and LinkedIn.
About Biom TherapeuticsBiom Therapeutics, a
clinical stage biopharmaceutical company, was founded by a team of
business leaders, scientists, and clinicians with a focus on
developing therapeutics for hard-to-treat neurological diseases.
Biom Therapeutics has positioned itself to be a world-class biotech
firm that improves human health and quality of life by developing
innovative drugs for treating and possibly reversing the effects of
hard-to-treat diseases, including rare forms of epilepsy and
autism. Biom's immediate goal is to bring practical treatment into
current medical practice as quickly as possible.
Please visit: https://biomtherapeutics.com/
Clever Leaves Press Contacts:Rich
DiGregorioKCSA Strategic
Communications+1-856-889-7351cleverleaves@kcsa.com
Diana SigüenzaStrategic Communications
Director+57-310-236-8830diana.siguenza@cleverleaves.com
Clever Leaves Commercial Inquiries:Andrew
Miller Vice President Sales - EMEA, North America, and
Asia-Pacific+1-416-817-1336andrew.miller@cleverleaves.com
Clever Leaves Investor Inquiries:Cody Slach and
Jackie KeshnerGateway Investor
Relations+1-949-574-3860CLVR@gatewayir.com
Biom Therapeutics Press ContactBobban
SubhadraChief Executive
Officer+1-941-552-8417bsubhadra@biomtherapeutics.com
John AllenPresident+1-204-1401jallen@biomtherapeutics.com
Clever Leaves (NASDAQ:CLVR)
Historical Stock Chart
From Feb 2023 to Mar 2023
Clever Leaves (NASDAQ:CLVR)
Historical Stock Chart
From Mar 2022 to Mar 2023